Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 20, 2017
Pharmacy Choice - Pharmaceutical News - Novaliq GmbH Announces Licensing Agreement with AFT Pharmaceuticals for the Distribution of NovaTears - August 20, 2017

Pharmacy News Article

 3/20/17 - Novaliq GmbH Announces Licensing Agreement with AFT Pharmaceuticals for the Distribution of NovaTears

NovaTears, A Novel Treatment for Dry Eye Disease, Is Now Available in Australia and New Zealand

HEIDELBERG, Germany(BUSINESS WIRE) Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (AFT) for the commercialization of Novaliq's lead product NovaTears in Australia and New Zealand.

NovaTears is Novaliq's first commercially available ophthalmic product for the treatment of evaporative dry eye diseases (DEDs). In Europe, NovaTears is distributed by URSAPHARM under the brand name EvoTears.

Under the terms of the agreement, Novaliq has granted AFT an exclusive license for the commercialization of NovaTears across Australasia. In return for these rights, Novaliq will receive an undisclosed upfront payment and royalties on net sales of NovaTears.

Novaliq is delighted to collaborate with AFT, a leading and innovative pharmaceutical company with a strong commitment to eye care, said Christian Roesky, PhD, CEO, Novaliq. NovaTears provides a highly differentiated and clinically validated treatment option that significantly improves the signs and symptoms of evaporative DED and Meibomian gland dysfunction (MGD), highly underserved diseases. We are confident that dry eye patients in Australasia will greatly benefit from the use of NovaTears and our partnership with AFT.

AFT is dedicated to bringing innovative products to market that make a real difference to people's health, said Hartley Atkinson, MD, CEO, AFT. The addition of NovaTears to our eye care line will be welcomed by doctors and patients alike. It's a first-in-class, water-free and preservative-free treatment based on Novaliq's proprietary EyeSol technology platform. NovaTears supports the lipid layer of the tear film by its ability to quickly spread and be absorbed into the eye. We believe that this feature combined with its small droplet size will provide superior benefits to patients with evaporative dry eye disease.

About NovaTears

NovaTears, the first product developed and commercialized that incorporates Novaliq's proprietary EyeSol technology, is an innovative multi-dose, non-aqueous and preservative-free topical eye drop for the lubrication of the ocular surface. The NovaTears droplet forms a thin and smooth protecting film supporting the lipid layer in its function to prevent tear evaporation for the relief of dry eye and irritated eye symptoms. NovaTears has been classified as a class ?a medical device and received CE mark approval in Europe in July 2013. Open, prospective, uncontrolled post-market clinical studies NT-001 and NT 002 successfully demonstrated safety and significant improvement in signs and symptoms of dry eye disease and Meibomian gland dysfunction. All results of the study point towards excellent clinical performance, safety and very high convenience and acceptance of NovaTears for patients suffering from hyper-evaporative dry eye.

About AFT Pharmaceuticals AFT founded in 1997 is an Auckland, New Zealand-based pharmaceuticals company operating in Australia, New Zealand and the Pacific Islands. AFT is listed on the Australian [ASX] and New Zealand [NZX] stock exchanges since December 2015 and has significant local sales operations in Australasia together with R&D activities in pain, orphan drugs and medical devices.

About Novaliq Novaliq GmbH, founded in 2004, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq's proprietary EyeSol technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq's most advanced product is NovaTears with CE-marking based on Novaliq's proprietary EyeSol technology. NovaTears is marketed under the brand name EvoTears in Europe. More on www.novaliq.com.

Novaliq

Michael ORourke, + 1 813-323-1438

Strategic Consultant

mo'rourke@novaliq.com

or

AFT

Ryan Malone, + 64 21 205 5149

Dart Public Affairs

ryan.malone@dartpublicaffairs.co.nz

Source: Novaliq



Copyright Business Wire 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Aug 21: An Integrative Approach to Managing Arthritis
Aug 22: Men's Health
Aug 23: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Aug 24: Treatment of Parkinson's Disease and Comorbid Conditions
Aug 25: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415